These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8020048)

  • 1. [Anti-angina activity of potassium-channel activators].
    Chiariello M; Duilio C; Ambrosio G
    Cardiologia; 1993 Dec; 38(12 Suppl 1):459-63. PubMed ID: 8020048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries.
    Nielsen-Kudsk JE
    Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [K-channel activators and cardioprotection].
    Specchia G; Marsico F; Laudisa ML
    Cardiologia; 1993 Dec; 38(12 Suppl 1):453-7. PubMed ID: 8020047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure].
    Satoh K
    Nihon Rinsho; 1993 May; 51(5):1293-8. PubMed ID: 8331797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy.
    Krumenacker M; Roland E
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S93-102. PubMed ID: 1282184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATP-sensitive K+ channel openers: old drugs with new clinical benefits for the heart.
    Miura T; Miki T
    Curr Vasc Pharmacol; 2003 Oct; 1(3):251-8. PubMed ID: 15320472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pinacidil but not nicorandil opens ATP-sensitive K+ channels and protects against simulated ischemia in rabbit myocytes.
    Critz SD; Liu GS; Chujo M; Downey JM
    J Mol Cell Cardiol; 1997 Apr; 29(4):1123-30. PubMed ID: 9160864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nicorandil: a potassium channel opening drug for treatment of ischemic heart disease.
    Goldschmidt M; Landzberg BR; Frishman WH
    J Clin Pharmacol; 1996 Jul; 36(7):559-72. PubMed ID: 8844437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of K+ channel opening and stimulation of cyclic GMP in the vasorelaxant effects of nicorandil in isolated piglet pulmonary and mesenteric arteries: relative efficacy and interactions between both pathways.
    Pérez-Vizcaíno F; Cogolludo AL; Villamor E; Tamargo J
    Br J Pharmacol; 1998 Mar; 123(5):847-54. PubMed ID: 9535012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of potassium channel activators in coronary heart disease.
    Haeusler G; Lues I
    Eur Heart J; 1994 Aug; 15 Suppl C():82-8. PubMed ID: 7995277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicorandil for angina.
    Drug Ther Bull; 1995 Dec; 33(12):89-92. PubMed ID: 8777891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inotropic and coronary vasodilatory actions of the K-adenosine triphosphate channel modulator nicorandil in human tissue.
    Müller-Ehmsen J; Brixius K; Hoischen S; Schwinger RH
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1220-8. PubMed ID: 8968344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical use of potassium channel activators in angina pectoris: efficacy and tolerance].
    Specchia G; Marsico F; Micheletti T; Bona M
    Cardiologia; 1995 Dec; 40(12 Suppl 1):91-5. PubMed ID: 8998788
    [No Abstract]   [Full Text] [Related]  

  • 14. A potassium channel opener as monotherapy in chronic stable angina pectoris: comparison with placebo.
    Why HJ; Richardson PJ
    Eur Heart J; 1993 Jul; 14 Suppl B():25-9. PubMed ID: 8370369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of administration of nicorandil or bimakalim prior to and during ischemia or reperfusion on survival rate, ischemia/reperfusion-induced arrhythmias and infarct size in anesthetized rabbits.
    Das B; Sarkar C; Karanth KS
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Nov; 364(5):383-96. PubMed ID: 11692221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of potassium channel openers.
    Andersson KE
    Pharmacol Toxicol; 1992 Apr; 70(4):244-54. PubMed ID: 1535127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potassium channel activators in the management of ischaemic heart disease: a focus on nicorandil.
    Purcell H; Fox K
    Br J Clin Pract; 1993; 47(3):150-4. PubMed ID: 8347442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.
    Frampton J; Buckley MM; Fitton A
    Drugs; 1992 Oct; 44(4):625-55. PubMed ID: 1281076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperpolarized cardioplegic arrest with nicorandil: advantages over other potassium channel openers.
    Jayawant AM; Lawton JS; Hsia PW; Damiano RJ
    Circulation; 1997 Nov; 96(9 Suppl):II-240-6. PubMed ID: 9386105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nicorandil on cytosolic calcium concentrations and on tension development in the rabbit femoral artery.
    Abe S; Nishimura J; Nakamura M; Kanaide H
    J Pharmacol Exp Ther; 1994 Feb; 268(2):762-71. PubMed ID: 8113988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.